Evaluation of MTHFR C677T gene polymorphism and homocysteine level in coronary atherosclerotic disease;Avaliação da relação entre o polimorfismo C677T no gene para MTHFR e a concentração plasmática de homocisteína na doença arterial coronariana

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 6, 2006, Pages 1059-1065

  Muniz, Maria Tereza Cartaxo ^b,d   Siqueira, Erika R F ^b   Fonseca, Rosana A ^b   D'Almeida, Vânia ^a   Hotta, Júlia K ^c   Dos Santos, José E ^c   Cavalcanti, Maria Do S M ^b   Sampaio, Cláudio A M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d NONE   (Brazil)

Author keywords

Coronary arterial disease; Dislipidemias; Folate; Homocysteine; Methylenetetraidrofolate reductase; Polymorphism

Indexed keywords

EID: 33846378138     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000600012     Document Type: Article

References (31)

1. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extra cranial carotid-artery stenosis. N Engl J Med 1995;332:286-91.
2. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for cardiovascular disease: The European concerted action Project. JAMA 1997;277:1775-81.
3. Guba SC, Fink IM, Fonseca V. Hyperhomocysteinemia an emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pat 1996;105:709-22.
4. Wolfgang H, Obeid R, Jouma M. Hyperhomocysteinemia and vitamin B-12 deficiency are more striking in Syrians than in Germans - causes and implications. Atherosclerosis 2003;166:143-50.
5. Van den Brandhof WE. The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001;157:403-9.
6. Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N, et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999;100:2406-10.
7. Tsai MY, Welge BG, Hanson NQ, Bignell MK, Vessey J, Schwichtenberg K, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Artherosclerosis 1999;143:163-70.
8. Chao CL, Tsai HH, Lee CM, Hsu SM, Kao JT, Chien KL, et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 1999;147:379-80.
9. Yoo JH, Park JE, Hong KP, Lee SH, Kim DK, Lee WR, et al. Moderate hyperhomocysteinemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans. Thromb Res 1999;94:45-52.
10. Anderson JL, Muhlesteim JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-32.
11. Verhoef P, Kok FJ, Kluijtmans LAJ, Refsum H, Veland PM, Kruysen DACM. The 677 C→T mutation in methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997;132:105-13.
12. Andreassi MG, Botto N, Cocci F, Battaglia D, Antonioli E, Masetti S, et al. Methylenetetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Hum Genet 2003;112:171-7.
13. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in metylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in diferent European populations. Atherosclerosis 1998;136:347-54.
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. N Genet 1995;10:111-3.
15. Yoo J, Park S-C. Low plasma folate in combination with the C677T metthylenetetrahydrofolate reductase polymorphism is associated with increased risk of coronary artery disease in Koreans. Thromb Res 2000;97:77-84.
16. Gemmati D, Serino ML, Trivellato C, Fiorini S, Scapoli GL. C677T substitution in methylenetetrahydrofolate reductase gene as a risk factor for venous thrombosis and arterial disease in selected patients. Heamatologica 1999;84:824-8.
17. Jee SH, Beaty TH, Suh I, Yoon Y, Appel LJ. The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis 2000;153:161-8.
18. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. Methylenetetrahydrofolate reductase C677T mutation plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998;9:4158-63.
19. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. N Struct Biol 1999;6:359-65.
20. Pfeiffer CM, Huff DL, Gunter EW. Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem 1999;45:290-2.
21. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.
22. Botto N, Andreassi MG, Manfredi S, Masetti S, Cocci F, Colombo MG, et al. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur J Hum Genet 2003;11:671-8.
23. Heijer M, Brouwer IA, Bos GMJ. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-61.
24. van der Griend R, Haas FJ, Biesma DH, Duran M, Meuwissen OJ, Banga JD. Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives. Atherosclerosis 1999;143:177-83.
25. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G, et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999;146:133-40.
26. Lobo A, Naso A, Arheart K, Kruger WD, Abou-Ghazala T, Alsous F, et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol 1999;83:821-5.
27. Kruger WD, Evans AA, Wang L, Malinow MR, Duell PB, Anderson PH, et al. Polymorphisms in the CBS gene associated with decreased risk of coronary artery disease and increased responsiveness to total homocysteine lowering by folic acid. Mol Metab 2000;70:53-60.
28. Mager A, Battler A, Birnbaum Y, Magal N, Shohat M. Plasma homocysteine, methylenetetrahydrofolate reductase genotypes and age at onset of symptoms of myocardial ischemia. Am J Cardiol 2002;89:919-23.
29. Wu AH, Tsongalis GJ. Correlation of polymorphism to coagulation and biochemical risk factors for cardiovascular disease. Am J Cardiol 2001;87:1361-6.
30. Ho CH, Kuo BI, Kong CW, Chau WK, Hsu HC, Gau JP, et al. Influence of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, B vitamins and other factors on plasma homocysteine and risk of thromboembolic disease in Chinese. J Chin Med Assoc 2005;68:560-5.
31. Gueant-Rodriguez RM, Juilliere Y, Candito M, Adjalla CE, Gibelin P, Herbeth B, et al. Association of MTRRA66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost 2005;94:510-5.